logo-loader
HemoGenyx Pharmaceuticals

Hemogenyx soars as CDX antibody demonstrates effectiveness against acute myeloid leukemia

Vladislav Sandler, the company’s chief executive, said the firm was “encouraged” by the results

Cancer ribbon
AML accounts for roughly 1.8% of cancer deaths in the US

HemoGenyx Pharmaceuticals PLC (LON:HEMO) shares soared on Wednesday after first data from an animal study of its CDX antibody, designed to treat a form of blood cancer, showed that the treatment was effective in eliminating a subset of cells.

CDX is being developed to treat acute myeloid leukemia (AML), a condition that accounts for roughly 1.8% of cancer deaths in the US with more than 20,000 new cases diagnosed in the US and 18,000 cases in Europe every year.

Vladislav Sandler, the company’s chief executive, said the firm was “encouraged” by the latest results. He added that if successful, CDX could provide a new and potentially effective treatment for AML.

It is estimated that the value of the global therapeutic market for AML was about US$700mln in 2018 and it is expected to grow to more than US$1.5bn by 2024.

In early deals, the company’s shares were up 16.7% at 2.8p.

Quick facts: HemoGenyx Pharmaceuticals

Price: £0.03

Market: LSE
Market Cap: £9.39 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of HemoGenyx Pharmaceuticals named herein, including the promotion by the Company of HemoGenyx Pharmaceuticals in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

HemoGenyx CEO 'overwhelmed' by speed of progress at the company

Dr Vladislav Sandler, chief executive of HemoGenyx Pharmaceuticals PLC (LON:HEMO), caught up with Proactive's Andrew Scott while in London to meet with investors. It's been nearly nine months now since the company first listed in London and in that time they've inked four collaborations...

on 27/6/18

2 min read